Results 161 to 170 of about 1,643 (210)
Some of the next articles are maybe not open access.
Dehydrocrenatidine Is a Novel Janus Kinase Inhibitor
Molecular Pharmacology, 2015Janus kinase (JAK) 2 plays a pivotal role in the tumorigenesis of signal transducers and activators of transcription (STAT) 3 constitutively activated solid tumors. JAK2 mutations are involved in the pathogenesis of various types of hematopoietic disorders, such as myeloproliferative disorders, polycythemia vera, essential thrombocythemia, and primary ...
Jing, Zhang +10 more
openaire +2 more sources
Zeitschrift fur Rheumatologie, 2022
In 2017 the first Janus kinase (JAK) inhibitors were approved for the treatment of rheumatoid arthritis in Germany. The mode of action of JAK inhibitors differs from biologicals, as multiple cytokines are inhibited. In comparison with the treatment with biologicals, JAK inhibitors have the advantage of oral application, three of the four currently ...
openaire +1 more source
In 2017 the first Janus kinase (JAK) inhibitors were approved for the treatment of rheumatoid arthritis in Germany. The mode of action of JAK inhibitors differs from biologicals, as multiple cytokines are inhibited. In comparison with the treatment with biologicals, JAK inhibitors have the advantage of oral application, three of the four currently ...
openaire +1 more source
Zeitschrift fur Rheumatologie, 2013
Janus protein tyrosine kinase (JAK) inhibitors are new therapeutic targets in the treatment of rheumatoid arthritis. Tofacitinib has shown good clinical efficacy in phase II and III studies with American College of Rheumatology (ACR) 20 response rates over 50% for monotherapy and in combination with methotrexate (MTX).
E, Ostermeier, P, Roll, H-P, Tony
openaire +1 more source
Janus protein tyrosine kinase (JAK) inhibitors are new therapeutic targets in the treatment of rheumatoid arthritis. Tofacitinib has shown good clinical efficacy in phase II and III studies with American College of Rheumatology (ACR) 20 response rates over 50% for monotherapy and in combination with methotrexate (MTX).
E, Ostermeier, P, Roll, H-P, Tony
openaire +1 more source
[Pharmacology of Janus kinase inhibitors].
Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2019Modern dermatotherapy is dominated by the development of various biologicals and small molecules. Janus kinase inhibitors (JAKi) form a novel class of small molecular synthetic compounds inhibiting the intracellular signal transduction of cytokine receptors. Cytokines are key mediators in the pathophysiology of numerous inflammatory skin diseases. Many
F, Solimani, F J, Hilke, K, Ghoreschi
openaire +2 more sources
Thromboembolism and Janus Kinase Inhibitors
Drug Safety, 2020Fowzia Ibrahim, David L. Scott
openaire +3 more sources
Janus kinase inhibitors for rheumatoid arthritis
Current Opinion in Chemical Biology, 2016Treatment of autoimmune diseases, such as rheumatoid arthritis (RA), has advanced substantially over the past decade with the development of biologics targeting inflammatory cytokines. Recent progress in treating RA has been achieved with janus kinase (JAK) inhibitors (Jakinibs), an orally available disease-modifying anti-rheumatic drug targeting the ...
openaire +2 more sources
Potential Use of Janus Kinase Inhibitors in the Treatment of Systemic Lupus Erythematosus
Journal of Inflammation Research, 2023Xinxiang Huang, Jinying Lin
exaly
The Use of Janus Kinase Inhibitors in Axial Spondyloarthritis: Current Insights
Pharmaceuticals, 2022Eric Toussirot, Toussirot Eric
exaly